Abstract 1837P
Background
Prior data have shown that prostate specific antigen (PSA) ≤ 0.2 ng/dL with androgen deprivation therapy (ADT) is prognostic for OS. We explored whether PSA ≤ 0.2 ng/dL at 4-7 months post randomization is a valid surrogate for OS in men with mHSPC. If so, it could be used to expedite phase 3 clinical trials. This hypothesis was investigated by the STOPCAP M1 Collaboration.
Methods
Individual patient data (IPD) from 13 eligible randomized trials comparing treatment regimens (ADT or docetaxel in the control or research arms in mHSPC) were utilized. We considered PSA measurements collected post randomization and evaluated the surrogacy of PSA ≤ 0.2 ng/dL at 4-7 months at the patient and trial levels. We utilized the proportional hazards model and estimated the hazard ratios (HR) for PSA ≤ 0.2 ng/dL predicting OS. We also fitted weighted linear regression, stratified by trial and treatment arm, and computed R2 to quantify the proportion of variance that was explained by the regressions. We defined a priori clinically relevant surrogacy of R2 value greater than 0.75. Lastly, we computed the surrogate threshold effect (STE), which is the minimum PSA treatment effect necessary to estimate a non-zero effect on OS.
Results
IPD from 5513 pts randomized from 1994-2012 from 13 trials were pooled for a stratified analysis. There were 3324 deaths, of which 70.5% were due to prostate cancer. The median follow-up was 74 months. At 4-7 months, the proportion of patients who had PSA ≤0.2 was 25.8%. At the individual level, PSA ≤0.2 ng/dL was a strong predictor of OS. Median OS in patients who experienced PSA≤0.2 and the results for the surrogacy analysis are presented in the table.
Table: 1837P
PSA<=0.2 ng/dL (n=1425) | PSA>0.2 ng/dL (n=4088) | |
Median OS months (95%CI) | 91.6 (85.1-98.2) | 40.9 (39.3-42.7) |
Hazard Ratio (95% CI) | 2.5 (2.3-2.7) | |
Condition 2 | 0.93 (0.78-0.99) | |
STE | 0.75 |
Conclusions
PSA≤0.2 ng/dL at 4-7 months met the surrogacy criteria and appears to be a valid surrogate endpoint for OS in men with mHSPC treated with ADT as back-bone hormonal therapy. Validation of this endpoint in trials with drugs having other mechanisms of action is planned.
Clinical trial identification
NCT00002651, NCT00216060, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00685646.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Prostate Cancer Foundation UK Prostate Cancer.
Disclosure
S. Halabi: Financial Interests, Personal, Other, Member of DSMB: Sanofi, Aveo Oncology, BMS, Janssen; Financial Interests, Institutional, Funding: ASCO. M.K. Parmar: Financial Interests, Institutional, Full or part-time Employment, Director at MRC Clinical Trials Unit at UCL: Medical Research Council Clinical Trials Unit at UCL; Financial Interests, Institutional, Research Grant: AstraZeneca, Astellas, Janssen, Clovis; Non-Financial Interests, Advisory Role, Euro Ewing Consortium: University College London; Non-Financial Interests, Advisory Role, rEECur: University of Birmingham; Non-Financial Interests, Advisory Role, CompARE Trial: University of Birmingham. M. Hussain: Financial Interests, Personal, Advisory Board: AstraZeneca, Janssen Pharmaceuticals, Merck & Co, Novartis, Pfizer, Bayer, Tempus Health, Convergent; Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Medscape, Merck, MLI Peer View, Research To Practice (RTP), Great Debates and Updates in GU Oncology; Financial Interests, Institutional, Research Funding: Arvinas, AstraZeneca, Bayer, Genentech. I.M. Thompson: Financial Interests, Personal, Coordinating PI, Clinical trial. Relationship has ended: Magforce; Financial Interests, Personal, Steering Committee Member, investigator in clinical trial: AbbVie. M.J. Morris: Financial Interests, Personal, Advisory Board: Oric, Pfizer, Exelixis, Lantheus, AstraZeneca, Amgen, Daiichi Sankyo, Convergent, Clarity Pharmaceuticals, Blue Earth Diagnostics, POINT Biopharma, Telix, Z-alpha; Financial Interests, Personal, Invited Speaker: Progenics, ITM Isotope Technologies; Financial Interests, Personal, Stocks/Shares: Doximity; Financial Interests, Institutional, Coordinating PI: Novartis, Celgen; Financial Interests, Institutional, Local PI: Corcept, Janssen, Astellas; Non-Financial Interests, Advisory Role: Bayer, Janssen Oncology, Novartis; Other, Other, Travel to conference: AstraZeneca; Other, Other, Travel/lodging at conference: APCCC. G. Gravis: Financial Interests, Institutional, Invited Speaker: AAA, Amgen, Astellas, BMS, Janssen, MSD, Pfizer, Ipsen, AstraZeneca alliance Merck Pfizer, Bayer, Eisai; Financial Interests, Institutional, Advisory Board: Alliance Merck-Pfizer, BMS, Janssen, Pfizer, ipsen, Bayer, Eisai; Non-Financial Interests, Principal Investigator: BMS, Ipsen, Merck; Financial Interests, Institutional, Funding: Janssen; Financial Interests, Institutional, Coordinating PI: BMS. D. Dearnaley: Financial Interests, Personal, Advisory Role: Janssen Pharma; Financial Interests, Institutional, Research Grant: Cancer Research UK, National Institute for Health Research (NIHR) Biomedical Research Centre; Financial Interests, Personal, Proprietary Information: ICR. N.D. James: Financial Interests, Personal, Advisory Board, Advice around PARP inhibitors: AstraZeneca; Financial Interests, Personal, Advisory Board, Prostate cancer therapies: Janssen, Clovis, Novartis; Financial Interests, Institutional, Advisory Board, Assisted with submissions regarding licencing for abiraterone: Janssen; Financial Interests, Personal, Advisory Board, Docetaxel: Sanofi; Financial Interests, Institutional, Advisory Board, Providing STAMPEDE trial data to facilitate licence extensions internationally for docetaxel: Sanofi; Financial Interests, Personal, Advisory Board, Bladder cancer therapy: Merck; Financial Interests, Personal, Advisory Board, Advice around novel hormone therapies for prostate cancer: Bayer; Financial Interests, Personal, Invited Speaker, Lecture tour in Brazil August 2022 - speaking on therapy for advanced prostate cancer: Merck Sharp & Dohme (UK) Limited; Financial Interests, Institutional, Coordinating PI, Funding for STAMPEDE trial: Janssen, Astellas; Financial Interests, Institutional, Coordinating PI, Funding for RADIO trial bladder cancer: AstraZeneca. M.E. Buyse: Financial Interests, Personal, Stocks or ownership: IDDI. C. Sweeney: Financial Interests, Personal, Advisory Board, Consultancy: Genentech Roche, Bayer, Astellas, Pfizer, Pfizer, Sanofi, Lilly; Financial Interests, Personal, Other, Consultancy: Janssen; Financial Interests, Personal, Advisory Board: Point, Cellcentric; Financial Interests, Personal, Stocks/Shares: Leuchemix; Financial Interests, Institutional, Research Grant: Bayer, Janssen, Astellas, Pfizer, Dendreon, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1940P - Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials
Presenter: Richard Schlenk
Session: Poster session 15
1941P - Preliminary efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase II trial
Presenter: Haiyan Hu
Session: Poster session 15
1942P - Non-metastatic malignant phyllodes tumors of the breast (B-MPT): A retrospective analysis from a referral center
Presenter: Carmine Valenza
Session: Poster session 15
1944P - MAGE-A4 and NY-ESO-1 expression analysed in a synovial sarcoma tissue micro-array
Presenter: Lore De Cock
Session: Poster session 15
1945P - Diagnostic and therapeutic impact of liquid biopsy in soft tissue sarcomas: A case series
Presenter: Tarek Assi
Session: Poster session 15
1946P - Bladder primary sarcomas (BSar): A genomic landscape and clinical outcomes study
Presenter: ALINA BASNET
Session: Poster session 15
1947P - Predictors and outcomes of recurrent retroperitoneal liposarcoma: New insights into its recurrence patterns
Presenter: Huan Deng
Session: Poster session 15
1948P - Concordance of the pathological diagnosis between local institutional and central judgment in high-grade non-round-cell sarcomas: A supplementary analysis of JCOG1306
Presenter: Eisuke Kobayashi
Session: Poster session 15
1949P - Pegylated liposomal doxorubicin (PLD) combined with trabectedin as a treatment option in uterine sarcomas
Presenter: Laura Strobel
Session: Poster session 15